Treeline Biosci 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  SHR-2554 / Treeline Biosci
    Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase 2 trial. (Hall A; Poster Bd #: 475) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_757;    
    To be eligible for inclusion, pts had to fulfill the following criteria: 8 years or older; histologically confirmed advanced or metastatic ES with loss of INI1 or upregulated mRNA level of EZH2; progressive disease after at least one line of doxorubicin-containing chemotherapy; the presence of measurable disease according to RECIST 1.1; an ECOG performance status of 0-1. SHR-2554 showed promising efficacy and an acceptable safety profile in pts with refractory ES, warranting further investigation.
  • ||||||||||  SHR-2554 / Treeline Biosci
    Enrollment open, Trial initiation date:  SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma (clinicaltrials.gov) -  Feb 1, 2024   
    P3,  N=130, Recruiting, 
    SHR-2554 showed promising efficacy and an acceptable safety profile in pts with refractory ES, warranting further investigation. Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024
  • ||||||||||  SHR-2554 / Treeline Biosci, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase ?/? Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (clinicaltrials.gov) -  Dec 15, 2023   
    P1/2,  N=100, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2024
  • ||||||||||  SHR-2554 / Treeline Biosci
    Trial completion:  Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects (clinicaltrials.gov) -  Dec 5, 2023   
    P1,  N=20, Completed, 
    Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2024 Active, not recruiting --> Completed
  • ||||||||||  SHR-2554 / Treeline Biosci, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    Enrollment open, Combination therapy:  SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) -  Jun 15, 2023   
    P1/2,  N=100, Recruiting, 
    Conclusions SHR-2554 showed promising efficacy and an acceptable safety profile in pts with refractory ES, warranting further investigation. Not yet recruiting --> Recruiting
  • ||||||||||  SHR-2554 / Treeline Biosci
    Enrollment closed, Trial completion date, Trial primary completion date:  Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects (clinicaltrials.gov) -  Mar 7, 2023   
    P1,  N=18, Active, not recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Jan 2023 --> May 2023
  • ||||||||||  SHR-2554 / Treeline Biosci
    Enrollment closed, Trial completion date, Trial primary completion date:  A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects (clinicaltrials.gov) -  Jan 13, 2022   
    P1,  N=28, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Jan 2022
  • ||||||||||  SHR-2554 / Treeline Biosci
    Enrollment change, Trial primary completion date:  A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (clinicaltrials.gov) -  Nov 22, 2021   
    P1,  N=231, Recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Jan 2022 N=120 --> 231 | Trial primary completion date: Jun 2022 --> Feb 2023
  • ||||||||||  SHR-2554 / Treeline Biosci
    Enrollment change, Trial completion date, Trial primary completion date:  A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (clinicaltrials.gov) -  Feb 5, 2021   
    P1,  N=120, Recruiting, 
    Not yet recruiting --> Recruiting | N=170 --> 319 N=42 --> 120 | Trial completion date: Sep 2020 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Jun 2022
  • ||||||||||  Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
    Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases:  A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC (clinicaltrials.gov) -  Feb 5, 2021   
    P1/2,  N=9, Terminated, 
    N=42 --> 120 | Trial completion date: Sep 2020 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Jun 2022 N=100 --> 9 | Trial completion date: Jul 2021 --> Dec 2020 | Recruiting --> Terminated; According to the available data from the trial?the sponsor determined to terminate this study.
  • ||||||||||  SHR-2554 / Treeline Biosci, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    Enrollment open, Combination therapy, Metastases:  Phase ?/? Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (clinicaltrials.gov) -  Sep 22, 2020   
    P1/2,  N=100, Recruiting, 
    N=100 --> 9 | Trial completion date: Jul 2021 --> Dec 2020 | Recruiting --> Terminated; According to the available data from the trial?the sponsor determined to terminate this study. Not yet recruiting --> Recruiting